First Financial Corp’s Pacira BioSciences PCRX Stock Holding History

First Financial Corp’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-52	Closed	-$783	–	451
2024 Q3	$783	Hold	52	–	–	﹤0.01%	426
2024 Q2	$1.49K	Hold	52	–	–	﹤0.01%	443
2024 Q1	$1.52K	Buy	+52	New	+$1.6K	﹤0.01%	534

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

First Financial Corp's PCRX Position: Q4 2024 in Review

First Financial Corp sold out of Pacira BioSciences (PCRX) in Q4 2024, closing a stake of 52 shares — an estimated $783 sold.

First Financial Corp first reported a position in PCRX in Q1 2024 and held it in 3 quarters. The position peaked at $1.52K in Q1 2024. 233 funds tracked by Wall St. Rank hold PCRX as of Q4 2024.

First Financial Corp reported no remaining Pacira BioSciences position as of Q4 2024 after selling out during the quarter.
First Financial Corp sold 52 Pacira BioSciences shares in Q4 2024, an estimated $783.
First Financial Corp first reported a position in Pacira BioSciences in Q1 2024 and held it in 3 quarters.
First Financial Corp's Pacira BioSciences position peaked at $1.52K in Q1 2024.
233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2024.

Based on First Financial Corp's 13F filing for Q4 2024, filed 13 Jan 2025.